EGFR and non-small cell lung carcinoma: The third-generation EGFR inhibitors, which can selectively target both sensitising mutations and the T790 M mutation, have demonstrated the benefit of continuing EGFR TKI treatment beyond progression for patients with T790 M mutation-positive NSCLC [39].